Il13 promoter (-1055) polymorphisms associated with chronic obstructive pulmonary disease in Taiwanese.

Shih-Feng Liu,Yung-Che Chen,Chin-Chou Wang,Wen-Feng Fang,Chien-Hung Chin,Mao-Chang Su,Meng-Chih Lin
DOI: https://doi.org/10.3109/01902140902893644
2009-01-01
Experimental Lung Research
Abstract:Interlukin-13 (IL13) -1055 polymorphism has been implicated in the development of chronic obstructive pulmonary disease (COPD) in various studies with conflicting results. The aims of this study are to investigate whether I L 13 - 1055 polymorphism is associated with the development of COPD in Taiwanese smokers; and to determine if IL13 - 1055 polymorphism 5 associated with the severity of COPD. A case control study was conducted on. COPD patients (n = 85) and healthy smoker (n = 72). Genomic DNA was extracted for genotyping of IL13 sequencing and serum IL13 was measured using by enzyme-linked immunosorbent assay (ELISA). After adjusting smoking index and age confounding, the T-allelic frequencies of the H., 13 -1055 gene polymorphisms in COPD group are significantly higher than those in control group (18.8% versus 1.4%; P < .001; odds ratio [OR] = 29.3; 95% confidence interval [CI]: 5.9-145.3); and the frequencies of CT/TT genotypes in COPD group am significantly higher than those in control group (27.1% versus 2.8%; P <. 001; OR = 20.0; 95% CI: 3.9-100.8). In COPI) patients, stepwise linear regression shows IL 13 - 1055 T allele is the independent factor associated with forced expiratory volume in 1 second (P =. 00 7), but not associated with serum IL-13. In conclusion, IL13 - 1055 T allele is associated with the development and severity of COPD in Taiwanese smokers.
What problem does this paper attempt to address?